272 related articles for article (PubMed ID: 18280243)
1. Structure of a BCOR corepressor peptide in complex with the BCL6 BTB domain dimer.
Ghetu AF; Corcoran CM; Cerchietti L; Bardwell VJ; Melnick A; Privé GG
Mol Cell; 2008 Feb; 29(3):384-91. PubMed ID: 18280243
[TBL] [Abstract][Full Text] [Related]
2. Mechanism of SMRT corepressor recruitment by the BCL6 BTB domain.
Ahmad KF; Melnick A; Lax S; Bouchard D; Liu J; Kiang CL; Mayer S; Takahashi S; Licht JD; Privé GG
Mol Cell; 2003 Dec; 12(6):1551-64. PubMed ID: 14690607
[TBL] [Abstract][Full Text] [Related]
3. Molecular dynamics analysis of the interaction between the human BCL6 BTB domain and its SMRT, NcoR and BCOR corepressors: the quest for a consensus dynamic pharmacophore.
Granadino-Roldán JM; Obiol-Pardo C; Pinto M; Garzón A; Rubio-Martínez J
J Mol Graph Model; 2014 May; 50():142-51. PubMed ID: 24793055
[TBL] [Abstract][Full Text] [Related]
4. Specific peptide interference reveals BCL6 transcriptional and oncogenic mechanisms in B-cell lymphoma cells.
Polo JM; Dell'Oso T; Ranuncolo SM; Cerchietti L; Beck D; Da Silva GF; Prive GG; Licht JD; Melnick A
Nat Med; 2004 Dec; 10(12):1329-35. PubMed ID: 15531890
[TBL] [Abstract][Full Text] [Related]
5. Backbone resonance assignment of the BCL6-BTB/POZ domain.
Lin LY; Evans SE; Fairall L; Schwabe JWR; Wagner SD; Muskett FW
Biomol NMR Assign; 2018 Apr; 12(1):47-50. PubMed ID: 28929458
[TBL] [Abstract][Full Text] [Related]
6. Structural basis of Apt48 inhibition of the BCL6 BTB domain.
Zacharchenko T; Kalverda AP; Wright SC
Structure; 2022 Mar; 30(3):396-407.e3. PubMed ID: 34774129
[TBL] [Abstract][Full Text] [Related]
7. Corepressor SMRT binds the BTB/POZ repressing domain of the LAZ3/BCL6 oncoprotein.
Dhordain P; Albagli O; Lin RJ; Ansieau S; Quief S; Leutz A; Kerckaert JP; Evans RM; Leprince D
Proc Natl Acad Sci U S A; 1997 Sep; 94(20):10762-7. PubMed ID: 9380707
[TBL] [Abstract][Full Text] [Related]
8. The LAZ3/BCL6 oncogene encodes a sequence-specific transcriptional inhibitor: a novel function for the BTB/POZ domain as an autonomous repressing domain.
Deweindt C; Albagli O; Bernardin F; Dhordain P; Quief S; Lantoine D; Kerckaert JP; Leprince D
Cell Growth Differ; 1995 Dec; 6(12):1495-503. PubMed ID: 9019154
[TBL] [Abstract][Full Text] [Related]
9. Polycomb group and SCF ubiquitin ligases are found in a novel BCOR complex that is recruited to BCL6 targets.
Gearhart MD; Corcoran CM; Wamstad JA; Bardwell VJ
Mol Cell Biol; 2006 Sep; 26(18):6880-9. PubMed ID: 16943429
[TBL] [Abstract][Full Text] [Related]
10. Critical residues within the BTB domain of PLZF and Bcl-6 modulate interaction with corepressors.
Melnick A; Carlile G; Ahmad KF; Kiang CL; Corcoran C; Bardwell V; Prive GG; Licht JD
Mol Cell Biol; 2002 Mar; 22(6):1804-18. PubMed ID: 11865059
[TBL] [Abstract][Full Text] [Related]
11. Discovery of high-affinity BCL6-binding peptide and its structure-activity relationship.
Sakamoto K; Sogabe S; Kamada Y; Sakai N; Asano K; Yoshimatsu M; Ida K; Imaeda Y; Sakamoto JI
Biochem Biophys Res Commun; 2017 Jan; 482(2):310-316. PubMed ID: 27856253
[TBL] [Abstract][Full Text] [Related]
12. The BCL-6 POZ domain and other POZ domains interact with the co-repressors N-CoR and SMRT.
Huynh KD; Bardwell VJ
Oncogene; 1998 Nov; 17(19):2473-84. PubMed ID: 9824158
[TBL] [Abstract][Full Text] [Related]
13. Discovery of an Irreversible and Cell-Active BCL6 Inhibitor Selectively Targeting Cys53 Located at the Protein-Protein Interaction Interface.
Sameshima T; Yamamoto T; Sano O; Sogabe S; Igaki S; Sakamoto K; Ida K; Gotou M; Imaeda Y; Sakamoto J; Miyahisa I
Biochemistry; 2018 Feb; 57(8):1369-1379. PubMed ID: 29293322
[TBL] [Abstract][Full Text] [Related]
14. BCoR, a novel corepressor involved in BCL-6 repression.
Huynh KD; Fischle W; Verdin E; Bardwell VJ
Genes Dev; 2000 Jul; 14(14):1810-23. PubMed ID: 10898795
[TBL] [Abstract][Full Text] [Related]
15. Point mutations in BCL6 DNA-binding domain reveal distinct roles for the six zinc fingers.
Mascle X; Albagli O; Lemercier C
Biochem Biophys Res Commun; 2003 Jan; 300(2):391-6. PubMed ID: 12504096
[TBL] [Abstract][Full Text] [Related]
16. Interferon regulatory factor 8 (IRF8) interacts with the B cell lymphoma 6 (BCL6) corepressor BCOR.
Yoon J; Feng X; Kim YS; Shin DM; Hatzi K; Wang H; Morse HC
J Biol Chem; 2014 Dec; 289(49):34250-7. PubMed ID: 25331958
[TBL] [Abstract][Full Text] [Related]
17. BAZF, a novel Bcl6 homolog, functions as a transcriptional repressor.
Okabe S; Fukuda T; Ishibashi K; Kojima S; Okada S; Hatano M; Ebara M; Saisho H; Tokuhisa T
Mol Cell Biol; 1998 Jul; 18(7):4235-44. PubMed ID: 9632807
[TBL] [Abstract][Full Text] [Related]
18. Identification of Thiourea-Based Inhibitors of the B-Cell Lymphoma 6 BTB Domain via NMR-Based Fragment Screening and Computer-Aided Drug Design.
Cheng H; Linhares BM; Yu W; Cardenas MG; Ai Y; Jiang W; Winkler A; Cohen S; Melnick A; MacKerell A; Cierpicki T; Xue F
J Med Chem; 2018 Sep; 61(17):7573-7588. PubMed ID: 29969259
[TBL] [Abstract][Full Text] [Related]
19. Structure of the polycomb group protein PCGF1 in complex with BCOR reveals basis for binding selectivity of PCGF homologs.
Junco SE; Wang R; Gaipa JC; Taylor AB; Schirf V; Gearhart MD; Bardwell VJ; Demeler B; Hart PJ; Kim CA
Structure; 2013 Apr; 21(4):665-71. PubMed ID: 23523425
[TBL] [Abstract][Full Text] [Related]
20. Progress toward B-Cell Lymphoma 6 BTB Domain Inhibitors for the Treatment of Diffuse Large B-Cell Lymphoma and Beyond.
Ai Y; Hwang L; MacKerell AD; Melnick A; Xue F
J Med Chem; 2021 Apr; 64(8):4333-4358. PubMed ID: 33844535
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
